Revisión sistemática y meta-análisis de la eficacia de paxlovid en pacientes COVID-19
No Thumbnail Available
Date
2025
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El coronavirus 2019 o COVID-19, producido por el virus SARS-CoV-2, representó un gran desafío en la salud pública. Este virus puede afectar principalmente los pulmones, pero también compromete otros órganos, causando una amplia gama de síntomas que varían desde leves hasta severos, y en algunos casos, puede ser mortal. En esta investigación se evaluó eficacia de paxlovid en tratamiento de pacientes con COVID- 19 mediante una revisión sistemática y meta-análisis. La selección de las investigaciones se llevó mediante la siguiente ecuación; (“COVID-19” OR “SARS- COV2) AND (“paxlovid” OR “nirmatrelvir” OR “nirmatrelvir/ritonavir”) AND (“efficacy” OR “effect” OR “efficiency” OR “effectivity”). Las bases de datos utilizadas fueron Science Direct, Scopus, Medline y Google Scholar. Para evaluar los estudios seleccionados se utilizaron técnicas como; funnel plot, método trim and fill, forest plot, r-student, dffits, cook.d, cov.r, tau2.del, QE.del, hat y weight. Se concluyó que la eficacia del paxlovid mediante una revisión sistemática y meta-análisis, demostró tener efecto positivo en el tratamiento temprano, reduciendo la progresión de COVID-19, minimizando complicaciones y disminuyendo hospitalizaciones, sin embargo, la evidencia actual no permitió establecer su eficacia estadísticamente significativa en el tratamiento de COVID-19.
ABSTRACT Coronavirus 2019 or COVID-19, produced by the SARS-CoV-2 virus, represented a major public health challenge. This virus can primarily affect the lungs, but also involves other organs, causing a wide range of symptoms that vary from mild to severe, and in some cases, can be fatal. In this research, the efficacy of paxlovid in the treatment of patients with COVID-19 was evaluated by means of a systematic review and meta-analysis. The selection of research was carried out using the following equation; (“COVID-19” OR “SARS-COV2) AND (“Paxlovid” OR “nirmatrelvir” OR “nirmatrelvir/ritonavir”) AND (“efficacy” OR “effect” OR “efficiency” OR “effectivity”). The databases used were Science Direct, Scopus, Medline and Google Scholar. To evaluate the selected studies, techniques such as funnel plot, trim and fill method, forest plot, r-student, dffits, cook.d, cov.r, tau2.del, QE.del, hat and weight were used. It was concluded that the efficacy of paxlovid, through a systematic review and meta-analysis, demonstrated a positive effect in early treatment, reducing the progression of COVID-19, minimizing complications and reducing hospitalizations; however, the current evidence did not allow establishing its statistically significant efficacy in the treatment of COVID-19.
ABSTRACT Coronavirus 2019 or COVID-19, produced by the SARS-CoV-2 virus, represented a major public health challenge. This virus can primarily affect the lungs, but also involves other organs, causing a wide range of symptoms that vary from mild to severe, and in some cases, can be fatal. In this research, the efficacy of paxlovid in the treatment of patients with COVID-19 was evaluated by means of a systematic review and meta-analysis. The selection of research was carried out using the following equation; (“COVID-19” OR “SARS-COV2) AND (“Paxlovid” OR “nirmatrelvir” OR “nirmatrelvir/ritonavir”) AND (“efficacy” OR “effect” OR “efficiency” OR “effectivity”). The databases used were Science Direct, Scopus, Medline and Google Scholar. To evaluate the selected studies, techniques such as funnel plot, trim and fill method, forest plot, r-student, dffits, cook.d, cov.r, tau2.del, QE.del, hat and weight were used. It was concluded that the efficacy of paxlovid, through a systematic review and meta-analysis, demonstrated a positive effect in early treatment, reducing the progression of COVID-19, minimizing complications and reducing hospitalizations; however, the current evidence did not allow establishing its statistically significant efficacy in the treatment of COVID-19.
Description
Keywords
Paxlovid. Eficacia. Comorbilidades. COVID-19. Meta-análisis